PCI Biotech granted NOK 13.8 million from the Research Council
Our member PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”.
Author Archive for: oslocancer
Entries by oslocancer
Cancer Crosslinks 2017 will be streamed
Cancer Crosslinks 2017 on January 26 features a really interesting program with International and Norwegian thought leaders presenting recent findings within cancer research.
Dehns is now member of the Oslo Cancer Cluster
Dehns Patent and Trade Mark Attorneys recently joined the Oslo Cancer Cluster. Dehns is one of Europe’s largest firms of patent and trade mark attorneys and has a 40 year history of working with Norwegian organisations such as: Dynal, Inven2,Lytix Biopharma, Nextera, NMBU, NTNU, Nycomed, PCI Biotech and Photocure. As members, our aim is to […]
The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway
The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway
